Popular Articles

Nebraska Legislature Advances Ultrasound Viewing Bill
The Nebraska Legislature on Wednesday voted to advance a bill (L.B. 675) that would require abortion providers who perform ultrasounds on women seeking the procedure to tell women that a view of the fetus will be available and display the screen in a way that the image can be easily seen, the AP/Lincoln Journal Star reports. The bill also would require the state to compile a list of clinics that offer no-cost ultrasound services. State Sen. Brenda Council (D) criticized that particular provision, saying it would force the state Department of Health and Human Services to spend more taxpayer money.Lawmakers advanced the bill by voice vote after approving an amendment to clarify language surrounding the qualifications of health professionals performing ultrasounds. Advocates for the bill claim it would provide more information to women seeking abortion procedures, while opponents of the bill argue that it would allow the government to interfere in a private procedure. The bill faces a final vote before going to Gov. Dave Heineman (R). If the bill becomes law, Nebraska would join more than a dozen states that have similar laws, the AP/Journal Star reports (Ortiz, AP/Lincoln Journal Star, 5/27).
generic viagra online
Lower Empathic Responses To Outsiders' Pain Shown By Imaging Study
An observer feels more empathy for someone in pain when that person is in the same social group, according to new research in the July 1 issue of The Journal of Neuroscience. The study shows that perceiving others in pain activates a part of the brain associated with empathy and emotion more if the observer and the observed are the same race. The findings may show that unconscious prejudices against outside groups exist at a basic level.
News of the day
USC Researchers Identify DNA Mutation That Occurs At Beginning Point Of T-Cell Lymphoma
Researchers at the Keck School of Medicine of the University of Southern California (USC) have identified a key mechanism that causes chromosomes within blood cells to break - an occurrence that marks the first step in the development of human lymphoma.
Public Health

Critical Marker Of Response To Gemcitabine In Pancreatic Cancer Identified By Jefferson Researchers

A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by researchers at Thomas Jefferson University. The protein, called Hu antigen R (HuR), is a stress response protein found in the cytoplasm of pancreatic tumor cells. In certain experimental settings, pancreatic cancer cells that overexpressed HuR were up to 30-fold more sensitive to gemcitabine (Gemzar), according to Jonathan Brody, Ph.D., assistant professor of Surgery at Jefferson Medical College of Thomas Jefferson University. In a clinical correlate study that included 32 resected pancreatic cancer patients who received gemcitabine, patients who had low cytoplasmic HuR levels had a 7-fold increased mortality risk compared to patients with high levels. This was after adjustment for other variables including age, sex, radiation therapy and other chemotherapy use. "This marker appears to tell us upfront whether a patient will respond to treatment with gemcitabine, which is the routine treatment for pancreatic cancer," said Dr. Brody, who is the senior author of the study. "Of course, larger and comprehensive prospective studies need to be performed, but we now have a real clue about how to make this treatment better. Finding a mechanism that regulates gemcitabine"s metabolism in pancreatic cancer cells is the real novel and exciting aspect of these findings." Dr. Brody and colleagues found that in pancreatic cancer, HuR helps to regulate an enzyme called deoxycytidine kinase (dCK), which is responsible for metabolizing and activating gemcitabine. As with most chemotherapy drugs, gemcitabine causes cell stress and activates the HuR stress proteins. In turn, the high levels of HuR stimulate the production of more dCK, thus making gemcitabine more efficient, according to Dr. Brody. "Normally, patients higher HuR cytoplasmic levels have a worse prognosis, since HuR expression is associated with advanced malignancies," Dr. Brody said. "However, in our study, they did better than patients with low HuR levels when they were treated with gemcitabine. We think it"s because they already have high HuR levels at the time of treatment, which may be a response to the tumor cell environment." According to Dr. Brody, research is underway to find a way to activate HuR in patients with a low expression. Other goals include expanding these findings to a larger pancreatic cancer population, and to other tumors that may be treated with gemcitabine, including breast, ovarian and certain lung cancers. They also want to determine if other chemotherapeutic agents engage this intriguing and manipulative pathway. Notes: Co-authors of the paper include Charles J. Yeo, M.D., Samuel D. Gross Professor and chairman of the department of Surgery, and Agnieszka Witkiewicz, M.D., assistant professor of Pathology, Anatomy and Cell Biology. Drs. Brody, Yeo and Witkiewicz are co-directors of the Jefferson Pancreas, Biliary and Related Cancer Center. Other study collaborators include Dr. Myriam Gorospe from the National Institute on Aging (NIH) and Dr. Judith Keen from the University of Medicine and Dentistry of New Jersey. Emily Shafer Thomas Jefferson University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):